Abstract Extranodal lymphomas are a diverse group of low and high grade neoplasms of B-, T-, and NK-cell lineage, each with characteristic sites of origin, morphology, immunophenotype, genetic features, patterns of spread, and prognosis. The diversity is sometimes seen even within a single histologic type of lymphoma. This phenomenon is especially striking in the category of diffuse large B-cell lymphoma (DLBCL). DLBCLs as classified in the WHO Classification are clinically and pathologically heterogeneous . Since the publication of the most recent edition of the WHO Classification of tumours of haematopoietic and lymphoid tissues ), a number of advances in the understanding of these lymphomas have been made. This review provides an overview of extranodal DLBCLs and describes recent updates regarding these lymphomas.
Introduction
Among cases of DLBCL, NOS there is clinical, morphologic, immunophenotypic, and genetic heterogeneity [1, 2] . There are subsets of DLBCL having phenotypes and gene expression profiles corresponding to origin from either germinal center-like B-cells or non-germinal center B-cells/activated B-cells, with differences in clinical behavior depending on the category [3, 4] . A subset of DLBCL, NOS with concurrent BCL2 and MYC rearrangements ("double-hit lymphomas") has a very poor prognosis [5, 6] . Recently, DLBCLs that express bcl2 and myc proteins (so-called "doubleexpressing lymphomas") have also been found to have a very poor prognosis, independent of the presence of underlying translocations [7] .
The variations within DLBCL are even more striking when considering the subtypes of DLBCL and the "other" lymphomas of large B-cells, as defined in the WHO Classification are considered (Table 1) [2] . The majority of these DLBCLs arise exclusively or frequently in extranodal sites, and those extranodal large B-cell lymphomas will be the focus of this discussion (Table 2) .
Primary central nervous system diffuse large B-cell lymphoma
Primary central nervous system diffuse large B-cell lymphoma (PCNSL) is defined as arising in the brain, spinal cord, eyes, or leptomeninges without evidence of prior or concurrent lymphoma outside the central nervous system [8] . It is a rare tumor, accounting for 3 % to 5 % of tumors primary in the central nervous system. PCNSL has a poor prognosis, although recent advances in therapy, in particular use of highdose methotrexate-based chemotherapy, offer some hope for patients with this disease. Patients are mostly older adults who present with neurological symptoms that are usually of short duration and that vary depending on the site of the lesion [9] [10] [11] . PCNSL usually presents as one or more intracranial lesions, but a few patients have isolated leptomeningeal disease, or rarely spinal cord involvement. In immunocompetent patients, intracranial lesions are more often solitary than multiple [9, 12] .
The characteristic microscopic appearance is a diffuse proliferation of large atypical lymphoid cells with areas of perivascular growth at the periphery of the lesion. Tumor cells are usually CD45+, CD20+, CD10−, bcl6+/−, bcl2+, MUM1/IRF4+, and monotypic immunoglobulin+, typically IgM. Thus, most cases have a non-germinal center immunophenotype [13] [14] [15] . Virtually all DLBCLs in immunosuppressed patients contain EBV [13, 14] , while PCNSL in immunocompetent patients is negative for EBV [16] .
The analysis of genetic abnormalities reveals a complex and heterogeneous set of changes. PCNSL is characterized by an unusually high load of somatic mutations in the variable regions of the immunoglobulin heavy chain (IGH) and light chain genes (IGL), suggesting prolonged participation of tumor cells or their precursors in the germinal center reaction [17] [18] [19] . Also seen is evidence of ongoing somatic hypermutation accompanied by intraclonal diversity [17, 18] . Aberrant somatic hypermutation is relatively frequent in a number of genes with roles in B-cell development and in regulation of proliferation and apoptosis, including PIM1, PAX5, RhoH/TTF, and MYC [20] . It is possible that the same mechanism that gives rise to the high frequency of somatic hypermutation in IGH and IGL may also be responsible for the aberrant hypermutation.
Chromosomal gains and losses are common. Among these, the most frequent are losses of 6p21 (HLA locus) and 6q, homozygous deletion of CDKN2A and gains of 12q12-q22 and 7q21 and 7q31 [10] . Somatic mutation of MYD88 (MYD88 L265P) is also common, being found in 38 % of the cases in one series [10] . MYD88 L265P mutations are fairly common in systemic DLBCL with an activated B-cell phenotype (29 % in one series) [21] and are nearly always present in cases of lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia [22] , so they are by no means unique to PCNSL. Certain abnormalities, including 6q22 loss and homozygous deletion of CDKN2A, a tumor suppressor gene, appear to be associated with inferior progression-free and overall survival [10] . Mutation of MYD88 is believed to promote lymphomagenesis via activation of the NFκB pathway; identification of this abnormality suggests that NFκB inhibitors may have a therapeutic role in the subset of PCNSL harboring mutated MYD88 [10] .
Primary cutaneous diffuse large B-cell lymphoma, leg type Primary cutaneous DLBCL, leg type is an uncommon primary cutaneous B-cell lymphoma that mainly affects elderly adults, with women more affected than men. It accounts for a minority of primary cutaneous B-cell lymphomas. The most common site of involvement is the lower leg, although other cutaneous sites may be affected [23] [24] [25] . It usually presents as solitary, occasionally multiple, erythematous or violaceous nodules on one or both legs, often with ulceration. The lesions in most cases are between 2 and 5 cm, although lesions larger than 5 cm are not uncommon. Lesions are infrequently <2 cm [23] . The treatment most commonly used is anthracyclinebased combination chemotherapy combined with rituximab, most often R-CHOP, with the addition of radiation in some cases. Radiation alone is sometimes utilized in these older patients [23] . Although most patients achieve a complete remission, relapses are common. The site most often involved in relapses is the skin, but some patients have progression to involve lymph nodes, central nervous system, and other sites [23] . The 5-year survival for DLBCL, leg type, is approximately 50 % [24] ; thus, among primary cutaneous B-cell lymphomas, it is relatively aggressive.
Microscopic examination reveals a diffuse dermal infiltrate of round, monomorphic large B-cells with prominent nucleoli and vesicular nuclei resembling immunoblasts and centroblasts. Admixed reactive cells are sparse. Epidermotropism is not a feature. Extension into the subcutis may occur. The usual immunophenotype is CD20+, CD79a+, CD10−, bcl6+/−, bcl2+, and MUM1/IRF4+ with a high proliferation index (Fig. 1) . Gene expression profiling studies revealed similarities between primary cutaneous DLBCL, leg type and ABC type of DLBCL, including activation of NFκB signaling [26] . Genetic abnormalities affecting multiple elements within the NFκB pathway have been identified in primary cutaneous DLBCL, leg type. These include heterozygous deletion of TNFAIP3 (A20), and mutations of CD79B, CARD11, and MYD88 resulting in amino acid substitutions, with more than one abnormality affecting a subset of cases [27] . The differential diagnosis of primary cutaneous DLBCL includes primary cutaneous follicle center lymphoma [25] . Cutaneous follicle center lymphoma is a proliferation of large and small centrocytes and centroblasts. In contrast to DLBCL, leg type, primary cutaneous follicle center lymphoma is composed of bcl6+, CD10+/−, bcl2−/dim, and MUM1/IRF4− tumor cells often associated with a CD21+ meshwork of follicular dendritic cells. A predominance of centroblasts or immunoblasts with strong expression of bcl2 and MUM1/IRF4 favors primary cutaneous DLBCL, leg type. DLBCL arising elsewhere and secondarily involving the skin could mimic primary cutaneous DLBCL, leg type. Clinical correlation and staging may be required to make a definite distinction.
EBV+ diffuse large B-cell lymphoma of the elderly EBV+DLBCL of the elderly is defined as an EBV+ clonal Bcell lymphoproliferation occurring in patients older than 50 years with no known immunodeficiency or prior lymphoma [28] . The etiology is believed to be related to the deterioration of immunity that may occur with advancing age. Many patients present with extranodal disease (GI tract, lungs, skin, soft tissue, tonsils). The composition may be monomorphous, with a predominance of large, atypical lymphoid cells which may have the appearance of immunoblasts or Reed-Sternberg cells and variants. In other instances the composition may be more polymorphous, with B-cells of a range of stages of maturation (including large atypical cells). There is a variable admixture of reactive cells, including histiocytes, small lymphocytes and plasma cells, and infrequently, eosinophils. Geographic necrosis is common. Tumor cells are usually CD20+ and/or CD79a+, CD10−, and often CD30+ and MUM1/IRF4+. CD15 expression is typically absent, but has been reported in a few cases. Nearly all cases have a non-germinal center B-cell immunophenotype [29, 30] . By definition, EBV is present in tumor cells. Based on immunohistochemical studies, the NFκB pathway appears activated in most cases [29] . Clonality studies disclose a clonal B-cell population in most cases. Of note, a clonal TCRγ rearrangement can be detected in a subset of cases, and likely represents a physiologic response to the EBV-infected neoplastic B-cells [29, 30] . Patients with EBV+DLBCL of the elderly have a relatively poor prognosis when compared to other DLBCL patients, even when they are compared to DLBCL patients of the same age [29, 30] .
EBV+DLBCL of the elderly may be especially problematic to distinguish from classical Hodgkin's lymphoma [28] . The cases in which Reed-Sternberg-like cells are conspicuous and admixed reactive cells are abundant can mimic classical Hodgkin's lymphoma. In favor of EBV+DLBCL of the elderly are involvement of extranodal sites unusual for involvement by Hodgkin's lymphoma, strong expression of B-cell markers, weak or absent expression of CD30, absence of CD15, absence of eosinophils, areas with solid growth of neoplastic cells, and EBER+ cells that are polymorphous (not all corresponding to cells with the appearance of ReedSternberg cells and variants). The presence of clonal T-cells may raise the question of T-cell lymphoma, but familiarity with the phenomenon of oligoclonal or clonal T-cell populations in association with EBV+B-cell proliferations (reactive and neoplastic) will help to avoid misdiagnosis.
Diffuse large B-cell lymphoma associated with chronic inflammation DLBCL associated with chronic inflammation is an EBV+ lymphoma arising in association with longstanding chronic, sometimes suppurative, inflammation resulting in localized immune dysregulation that may allow EBV+B-cells to escape immune surveillance and may promote B-cell proliferation, eventually leading to the development of lymphoma. The prototype of DLBCL associated with chronic inflammation is pyothorax-associated lymphoma, a rare EBV+DLBCL arising in the setting of tuberculosis treated with iatrogenic pneumothorax with resultant longstanding chronic pyothorax [31, 32] . Other clinical scenarios for this rare lymphoma include DLBCL arising in association with inflamed metal bone and joint implants, with chronic osteomyelitis, and with venous stasis ulcers. More recently, it is suggested that rare cases of EBV+DLBCL arising in cysts and pseudocysts, in long-standing hydrocele, in the stroma of atrial myxomas and in association with prosthetic cardiac valves should also be included in the category of DLBCL associated with chronic inflammation [33] [34] [35] [36] [37] . Microscopic examination reveals a proliferation of large atypical, sometimes bizarre and pleomorphic lymphoid cells, sometimes with plasmacytoid features, sometimes accompanied by extensive necrosis. The tumor cells may be scattered singly or in small clusters in a background of variably inflamed stroma or debris (Fig. 2) . Neoplastic cells typically have a post-germinal center immunophenotype: CD20+, CD79a+, CD10−, bcl6−, IRF4/MUM1+, and CD138+/−, with a high proliferation rate. In situ hybridization for EBER reveals the presence of EBV in tumor cells (Fig. 2c) . Pyothorax-associated lymphoma has a poor prognosis, although occasional patients have long-term survival. Some patients in the more recently described clinical settings have localized lymphomas that may have a good prognosis [31, 33, 34, 37, 38] . In contrast to pyothoraxassociated lymphoma, which is often associated with formation of a large mass and with marked chronic, suppurative inflammation, the lymphomas arising in cysts and pseudocysts and in the stroma of atrial myxomas typically do not comprise the majority of the mass lesion, and may be present as only microscopic collections of large atypical cells in tissue that is otherwise non-neoplastic. In addition, suppurative inflammation may be absent and chronic inflammation may be mild, suggesting that the pathogenesis may be distinct from that of pyothorax-associated lymphoma [34] . A consideration is that there is localized immune dysregulation within the closed space that the lymphomas arise in, so that EBV+B-cells are able to proliferate without control by cytotoxic T-cells [34] . Additional experience is needed to define the boundaries of DLBCL with chronic inflammation.
Lymphomatoid granulomatosis
Lymphomatoid granulomatosis was first described by Liebow and colleagues in 1972 as an angiocentric and angiodestructive lymphoreticular proliferation [39] . Lymphomatoid granulomatosis is now recognized as an angiocentric, angiodestructive EBV-positive B-cell lymphoproliferative disorder with a prominent component of reactive T-cells [40] [41] [42] . Lymphomatoid granulomatosis mainly affects adults with a male preponderance, with patients often being middle-aged [41] [42] [43] , although older adults [41, 43] and rarely children [43] are also affected. Although the majority of patients who develop lymphomatoid granulomatosis are not overtly immunodeficient, an underlying immunologic abnormality, which may be subtle, is almost always present [42, 44] .
In nearly all cases (>90 %), there is pulmonary involvement [42, 43] . Patients present with respiratory symptoms, constitutional symptoms, or both. Common symptoms include fever, cough, malaise, dyspnea, weight loss, chest pain, and hemoptysis. Some patients present with neurological symptoms related to central nervous system involvement or skin lesions related to cutaneous involvement [41] [42] [43] . The involvement of lymph nodes or spleen at presentation is uncommon [43, 44] .
Lung lesions are typically multiple and bilateral [43, 44] . The lesions are gray-white nodules, 1 to 5 cm in diameter [45] ; larger nodules are frequently necrotic [42] . 
Primary mediastinal (thymic) large B-cell lymphoma
Mediastinal large B-cell lymphoma is a lymphoma with distinctive clinical and pathologic features that arises in the thymus. The cell of origin is thought to be the asteroid cell of the thymus [47, 48] . Mediastinal large B-cell lymphoma mainly affects individuals between the age of 20 and 50 years with a female preponderance [49] [50] [51] [52] . Almost all patients have symptoms related to the presence of a mediastinal mass, including dyspnea, chest pain, cough, superior vena cava syndrome, or a combination of these [49] [50] [51] 53] .
Evaluation reveals an anterior superior mediastinal mass that is often large [50, 51] and often invades adjacent structures such as pleura, pericardium, lung, mediastinal soft tissue, blood vessels, and mediastinal lymph nodes. Pleural and pericardial effusions are common [50, 51] . In most cases, the lymphoma is confined to the thoracic cavity at presentation [50, 51] . With appropriate therapy, this lymphoma has a fairly good prognosis. Treatment failures may take the form of local recurrences or of extrathoracic relapses. The latter tend to involve extranodal sites such as kidneys, adrenal glands, gastrointestinal tract, central nervous system, ovaries, breasts, and others; although, lymph nodes may be involved as well [54] .
Microscopic examination reveals a diffuse infiltrate of atypical lymphoid cells, almost always associated with sclerosis. The sclerosis can be band-like, or it can be interstitial, or it can surround nests of cells, in a packeting pattern [55] . Small and large foci of necrosis are common. Neoplastic cells are typically large, often with irregular, lobated nuclei and clear cytoplasm. In some cases, neoplastic cells are centroblasts with round nuclei. Some cases show an admixture of immunoblasts or Reed-Sternberg-like cells [49, 56] . There is a variable admixture of small lymphocytes and histiocytes, but eosinophils are typically absent.
The neoplastic cells are diffusely positive for CD45, CD19, CD20, CD22, and CD79a. They are usually CD5−, CD10−, and bcl6+, with variable expression of bcl2 and CD30. Tumor cells in most cases do not express cell surface immunoglobulin. There is no evidence of EBV in tumor cells [47, 49, 54] . In contrast to DLBCL, NOS, CD23 is expressed by tumor cells in 70 % of cases; other DLBCLs infrequently express CD23 [47] .
Gene profiling studies [57] [58] [59] have also shown features characteristic of mediastinal large B-cell lymphoma. While the profile of mediastinal large B-cell lymphoma is different from that of other DLBCLs, it shows substantial overlap with that of classical Hodgkin's lymphoma [57] [58] [59] . These studies implicate constitutive activation of the JAK/STAT and the NFκB signaling pathways in the pathogenesis of this lymphoma [57] [58] [59] [60] . A complex interplay of elements contribute to the activation of these pathways, including amplification of areas of chromosomes with genes involved in promoting increased activity (such as amplification of 9p24, including JAK2), deletion of regions with tumor suppressor genes (such as TNFAIP3, which encodes A20), and mutation of tumors suppressor genes (such as SOCS1) [60] [61] [62] [63] . The evidence of NFκB activation can be demonstrated by immunohistochemistry as well [64] .
Eluding the immune response may also contribute to the pathogenesis of mediastinal large B-cell lymphoma. In 38 % of cases, mediastinal large B-cell lymphomas harbor a translocation involving HLA-class II transactivator (CIITA), which may result in downregulation of expression of major histocompatibility complex (MHC) class II, making neoplastic cells less vulnerable to immune attack [63, 65] . Programmed cell death ligand (PDL) 1 and PDL2 are thought to function by inactivating infiltrating T-cells, potentially promoting the growth of neoplastic B-cells. Amplification of 9q24, including the PDL locus, is common in mediastinal large B-cell lymphoma [66] . In a recent study, 29 % of cases of mediastinal large B-cell lymphoma showed amplification of the PDL locus, while 20 % of cases showed a rearrangement involving this locus using FISH [67] . Rearrangement correlated with increased PDL transcripts [67] . Nearly half of mediastinal large B-cell lymphomas express PDL1. However, comparison of PDL1+ and PDL1− cases of mediastinal large B-cell lymphoma reveals no prognostic differences [68] . Similarly, no significant differences regarding clinical features or outcome have been identified when comparing cases with PDL rearrangement, with PDL amplification, and without either amplification or rearrangement [67] . Thus, while genetic changes in mediastinal large B-cell lymphoma are heterogeneous, they result in a relatively uniform phenotype at the light microscopic and clinical level.
The differential diagnosis of mediastinal large B-cell lymphoma includes other DLBCLs (arising in mediastinal lymph nodes or secondarily involving the mediastinum), classical Hodgkin's lymphoma, and mediastinal gray zone lymphoma (discussed below) and carcinoma, especially well-differentiated thymic carcinoma. Compared to other DLBCLs, mediastinal large B-cell lymphoma is more likely to affect younger individuals and females, and to present with bulky, localized, mediastinal disease [58] . It has distinctive, although not entirely specific pathologic features, such as packeting sclerosis and frequent expression of CD23 that may help in making a distinction. In clinical and radiographic correlation, confirming the presence of a large mediastinal mass is helpful. Mediastinal large B-cell lymphoma and classical Hodgkin's lymphoma both tend to affect younger adults, with some female preponderance, and to produce mediastinal neoplasms that are characterized by a prominent sclerosis. Hodgkin's lymphoma usually arises in lymph nodes but in the mediastinum, may arise in the thymus [69] . Mediastinal large B-cell lymphoma is composed of large atypical cells, some of which may resemble Reed-Sternberg cells, that usually lack immunoglobulin and that may express CD30. Fewer admixed reactive cells, sheets of tumor cells, diffuse strong expression of B-cell antigens (including Pax5) [68] , absence of CD15, absence of strong CD30, co-expression of Oct2 and Bob1, expression of bcl6 [68] , and absence of eosinophils favor a diagnosis of mediastinal large B-cell lymphoma over Hodgkin's lymphoma. Mediastinal large B-cell lymphoma patients are also more likely to have a poor performance status and to have elevated LDH at presentation [68] . The packeting sclerosis frequently seen in mediastinal large B-cell lymphoma may mimic an epithelial neoplasm, and in this anatomic site, well-differentiated thymic carcinoma is a consideration, but careful evaluation of sections and a basic panel of immunostains establish a diagnosis.
Primary mediastinal gray zone lymphoma
This term has been used to describe lymphomas with features intermediate between those of mediastinal large B-cell lymphoma and classical Hodgkin's lymphoma, in which subclassification is difficult [70, 71] . The typical histologic appearance is that of sheets of tumor cells more pleomorphic than in the usual mediastinal large B-cell lymphoma, often resembling Hodgkin's cells, including lacunar variants. Reactive cells are more sparse than usually seen in classical Hodgkin's lymphoma, but a mixed infiltrate including eosinophils may be present. Necrosis may be present, but lacks the neutrophils often seen in Hodgkin's lymphoma with necrosis [72] . Immunophenotype is usually intermediate between Hodgkin's and diffuse large B-cell lymphoma. CD45 and CD30 are usually positive. CD15, Oct2, Bob1, and Pax5 are positive in most cases. B-cell markers, such as CD20 and CD79a, are often positive. ALK and immunoglobulin are not expressed [72] . Examples of gray zone lymphomas include a lymphoma with morphology consistent with mediastinal large B-cell lymphoma, but with an immunophenotype more like that of Hodgkin's lymphoma, or conversely, a lymphoma with the morphology of classical Hodgkin's lymphoma with abundant neoplastic cells but with diffuse, strong CD20 expression. A possibly related phenomenon is the rare occurrence of a composite lymphoma with distinct components of classical Hodgkin's lymphoma and diffuse large Bcell lymphoma, and the rare instance in which patients have both classical Hodgkin's lymphoma and diffuse large B-cell lymphoma in different sites, either synchronously or metachronously.
A critical issue which is under investigation is the optimal treatment for mediastinal gray zone lymphoma [71] . Gray zone lymphomas behave in a relatively aggressive manner, and therapy, as for an aggressive non-Hodgkin's lymphoma, including rituximab, in combination with radiation if required, has been suggested as being appropriate pending further investigation [73, 74] .
Intravascular large B-cell lymphoma
Intravascular large B-cell lymphoma is a rare neoplasm in which neoplastic cells are entirely or almost entirely confined to the lumens of vascular spaces. The pathogenesis of this lymphoma is uncertain, but it has been postulated that the neoplastic cells harbor a homing receptor defect or have defective expression of adhesion molecules [75] [76] [77] .
Intravascular large B-cell lymphoma affects middle-aged to older adults who present with subacute onset of protean symptoms related to vascular obstruction in a wide variety of extranodal sites, often accompanied by fever [75, 77, 78] . The variability in spectrum of symptoms, absence of a mass, and ability of this lymphoma to mimic non-neoplastic disorders make it challenging to diagnose. Intravascular large Bcell lymphoma is usually disseminated at presentation. In the classical, or Western form of the disease, sites commonly involved include the central nervous system, kidneys, adrenals, lungs, and skin, but many other sites, including liver, heart, gastrointestinal tract, and genitourinary tract can also be involved [75, [79] [80] [81] . The most common findings at presentation are related to central nervous system involvement; they include confusion, lethargy, dementia, seizures, abnormalities of gait, speech, vision, and others [75, 78] . Renal involvement often manifests as proteinuria and renal insufficiency; some patients have hematuria [77, 79, 82] . Depending on sites of involvement patients may have renal insufficiency, adrenal insufficiency, dyspnea, skin lesions, and others (Fig. 3) . There is a tendency to spare lymph nodes. A small proportion of patients present with intravascular lymphoma apparently confined to skin at presentation; these patients appear to have a better prognosis then most patients with intravascular large B-cell lymphoma [80, 83] . There is a recently described Asian variant of intravascular lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and hemophagocytosis [84] [85] [86] [87] ; the involvement of the skin and central nervous system is uncommon in the Asian variant, in contrast to the Western form of the disease.
Intravascular large B-cell lymphoma is traditionally associated with a poor prognosis, but this may be largely due to delay in diagnosis. Indeed, diagnosis is sometimes not established until a postmortem examination is performed. Patients promptly diagnosed and treated with chemotherapy with rituximab have a reasonably good prognosis [84, 87] .
The histological hallmark of this disorder is the finding of blood vessels that are filled and distended by large transformed lymphoid cells, usually with the appearance of centroblasts or immunoblasts, often without distortion of the architecture of the involved tissue. The infiltrate may be associated with thrombosis. Immunophenotyping shows that the neoplastic cells are typically CD45+, CD20+, CD19+, CD79a+, bcl2+, and MUM1/IRF4+ [75, 77, 87] . Coexpression of CD5 is not uncommon [88, 89] . CD10 and bcl6 are absent in most cases [81, 90] .
Plasmablastic lymphoma
Plasmablastic lymphoma is a distinctive variant of DLBCL that was first described in the oral cavity [91] . It is defined as a diffuse proliferation of large neoplastic cells, most with the morphology of immunoblasts, but with the immunophenotype Fig. 4 Plasmablastic lymphoma. a The lymphoma is composed of a diffuse proliferation of large atypical cells with the appearance of immunoblasts and plasmacytoid immunoblasts, with interspersed tingible body macrophages. Mitoses are frequent. Tumor cells are positive for lambda light chain (b) and negative for kappa (c; in situ hybridization on paraffin sections). They were also CD20−, CD138+, and HHV8− (immunostains not shown) Fig. 3 Intravascular large B-cell lymphoma involving the heart at autopsy. Large atypical lymphoid cells fill several blood vessels within myocardium of plasma cells [92] . Since its initial description, plasmablastic lymphoma has been found in other extranodal sites, including paranasal sinuses, gastrointestinal tract, bone, liver and spleen, testes, skin and soft tissue, and less often in lymph nodes [93] [94] [95] [96] . In the majority of cases patients present with advanced stage disease. Most patients with this type of lymphoma are HIV+ adults with a median age in the fifth decade and a striking male preponderance [96, 97] . Even among HIV+ individuals this type of lymphoma is uncommon; in one study, only 6 % of AIDS-related lymphomas were plasmablastic lymphomas [97] . In a minority of cases, the development of plasmablastic lymphoma is the first sign that the patient is HIV+ [96] . In most cases, however, patients have been HIV+ for years before the development of plasmablastic lymphoma, and some of them have received highly active anti-retroviral therapy (HAART), so that treatment with HAART does not serve as definitive protection against plasmablastic lymphoma [96] . Cases of plasmablastic lymphoma are also described in iatrogenically immunosuppressed patients and in HIV-negative, apparently immunocompetent individuals, mostly older adults, and rarely in children [93, 95, 98] . Compared to HIV+ patients with plasmablastic lymphoma, HIV-negative plasmablastic lymphoma patients are on average older, with a less striking male preponderance and are less likely to present with disease in the oral cavity [95, 99] .
The lymphoma is typically composed of a monotonous proliferation of large cells with the appearance of immunoblasts, plasmacytoid immunoblasts, or plasmablasts, with vesicular nuclei and prominent nucleoli (Fig. 4) . In other cases, there is plasmacytic differentiation, with a subset of cells showing maturation toward plasma cells. These neoplasms have a high mitotic rate, frequent single cell or zonal necrosis and scattered tingible body macrophages. The immunophenotype is closer to that of a plasma cell than to a normal B-cell: neoplastic cells are typically positive for CD138, CD38, and/or MUM1/IRF4; negative for CD20, Pax5, bcl6, and EBV-LMP; and with variable expression of CD45, CD79a, CD56, CD10, CD30, and cytoplasmic immunoglobulin (Fig. 4b, c) . In situ hybridization for EBER demonstrates EBV in most cases. Aberrant expression of keratin has been reported [91, [93] [94] [95] [96] [97] [98] [99] [100] . There is a high proliferation fraction among the neoplastic cells [92] [93] [94] . The proliferation index is greater than 80 % in approximately 80 % of cases [96, 97] . HIV-negative patients appear somewhat more likely to have EBV-negative plasmablastic lymphomas [95] . HHV8 is absent, by definition [92] . A translocation involving MYC and can be found in 40-50 % of cases, with the partner in most cases being IGH [t (8;14) ] [96, 98, 101, 102] . The MYC rearrangement is typically present in the setting of a complex karyotype, in contrast to Burkitt lymphoma. There is no rearrangement of BCL6 or BCL2 genes; thus, plasmablastic lymphoma is not part of the spectrum of so-called "doublehit" lymphomas [102] .
Plasmablastic lymphoma is an aggressive lymphoma with a poor prognosis, although a good response to treatment is achieved in a minority of cases. Factors suggested as predicting a poor prognosis include ECOG performance status of two or more, advanced stage disease, failure to achieve a complete remission, and MYC rearrangement [96] . Aggressive therapy, including autologous stem cell therapy, may improve the outcome. Some investigators suggest that treatment with agents useful in plasma cell myeloma may be efficacious in plasmablastic lymphoma [96, 97, 99] . The optimal therapy remains to be identified.
Primary effusion lymphoma
Primary effusion lymphoma, previously called body cavitybased lymphoma, is a rare, distinctive type of HHV8+ (human herpes virus 8, also known as Kaposi's sarcoma-associated herpes virus [KSHV] ) DLBCL characterized by lymphomatous effusions involving pleural, pericardial or peritoneal cavities unaccompanied by a solid mass [103, 104] . Primary effusion lymphoma affects young and middle-aged adults with males much more often affected than females. Nearly all patients are HIV-positive; they present late in the course of HIV infection and are often profoundly immunodeficient at the time they present with lymphoma. Only occasional patients are HIV-negative [105, 106] . This lymphoma has a very poor prognosis, although among HIV+ patients, the outcome may be better for those receiving highly active antiretroviral therapy (HAART) [107] . Death is due to lymphoma, sometimes complicated by opportunistic infection and/or Kaposi's sarcoma [108] .
The neoplastic cells are uniform and immunoblast-like, or pleomorphic and very large (Fig. 5) . Some are binucleated or multinucleated and some of them may resemble ReedSternberg cells. Neoplastic cells express CD45 and MUM1/IRF4, and typically lack CD20, Pax5, CD79a, bcl6, and immunoglobulin. CD138 and CD30 (Fig. 5c ) are sometimes expressed. There may be aberrant expression of T-cell associated antigens [104] . Immunoglobulin heavy and light chains are clonally rearranged. The HHV8+ tumor cells are usually co-infected by EBV [98, 103, 109, 110] .
Cases of HHV8+ lymphoma with morphologic, immunophenotypic, and genetic features similar to those of primary effusion lymphoma, but producing mass lesions in lymph nodes or in extranodal sites have also been described [110] [111] [112] . These have been called HHV8+ or KSHV+ solid lymphomas or extracavitary primary effusion lymphomas [110, 112, 113] , or KSHV+ solid immunoblastic/ plasmablastic DLBCLs (Fig. 6) [98, 114] . Compared to classic primary effusion lymphoma, extracavitary HHV8-associated large B-cell lymphoma appear slightly more likely to express pan B-cell antigens such as CD20 and CD79a and monoclonal immunoglobulin [115] . In one study, 29 % of solid PELs showed aberrant expression of CD3, potentially leading to misinterpretation as T-cell lymphoma, especially anaplastic large cell lymphoma [115] .
Conclusions
DLBCLs arising in extranodal sites are of a variety of distinct types. Establishing the correct diagnosis requires careful evaluation of routinely stained sections augmented by appropriate immunohistochemical and sometimes cytogenetic and genetic studies. Testing for the presence of EBV and HHV8 is essential to establish a diagnosis of DLBCL of certain types. Clinical information, such as age, gender and ethnicity of patient, anatomic distribution of disease, and immune status, frequently provide important clues to the diagnosis. 
